Straight to your inbox from Keith himself!

*Trusted by tens of thousands of savvy investors and traders around the world every day

☕ Most investors could double their shares and still not have enough

Nov 20, 2025

Howdy! 👋

The media would have you believe that Nvidia “re-ignited” the AI trade.

Thing is, it never went away in the first place.

At the risk of sounding like a broken record and very deliberately so on my part.

If you are not investing in the best, you will get left with the rest.

Here’s my playbook.

In my best bandleader voice…

A’ one and a’ Two – keepin’ the rhythm

And I hope you’re “in tune.”

I told you two things Monday during my first TV appearance of the week… a) that Nvidia could save the markets and b) that Walmart was the one to watch. (Watch)

Most investors could double their shares in both and still not have enough, imho.

3 – Hyperscaler debt = doom? Only if you flunked Econ 101

Nvidia definitely sent ‘em packing.

Yet, the bubble babblers just can’t give up.

Now they’re saying the real “AI bubble indicator” isn’t Nvidia’s results at all… it’s the debt behind the data-centre build-out.

Apparently, because – you know as they wag their finger in your face – hyperscalers are using debt to expand capacity, that means the whole AI boom is on “borrowed” time – pun absolutely intended. (Read) 🙄

Even well known investor Ray Dalio jumped in yesterday, saying we’re “definitely in a bubble”… right before admitting you shouldn’t sell yet because nothing is actually popping it. (Read)

You can’t make this stuff up.

Here’s what I want YOU to keep in mind

If Nvidia’s results show anything, it’s that we are still seriously early in a multi-year build-out and that there is unprecedented profit potential on offer.

Not late.

Not peaking.

Early.

There is an entirely new generation of millionaires being printed right now.

But hey, it’s a free country.

If you wanna buy something else because “valuations look better,” knock yourself out.

And be prepared to come to terms with folks who make different choices that come with a radically different and potentially far more profitable outcome in the years ahead.

Just sayin.

Keith’s Investing Tip: Bubble Babblers are simply permabears with better haircuts — loud, certain, and usually wrong at the precise moment it matters most. Both thrive on fear because fear sells, but neither builds wealth. Sure, they sound smart, but predicting 284.7 of the last 2 actual downturns doesn’t count for a whole lot in the scheme of things and it’s very dangerous for your money to follow ‘em. Eventually they’re right and won’t hesitate to let you know it but so is a busted clock twice a day. The real money comes from staying data-driven, keeping your emotions out of it, and buying the best companies you can while everyone else hyperventilates.

History shows very clearly that their panic and pontificating is almost always a great entry point for those wanting to build real wealth (and keep it).

4 – Fed minutes or a comedy special, it’s hard to tell these days

The latest Fed minutes show officials were deeply divided over last month’s rate cut. (Read)

Some argued the labour market is weakening while others insist that inflation is still too hot.

The result?

A growing chunk of the committee now thinks no additional cuts are needed this year — including December.

Traders, of course, have adjusted fast. The December cut that looked like a lock a few weeks ago is now about 1 in 3 with January “on deck.”

Classic Fed move… uncertainty first, clarity later. 🤦‍♂️

I told you on October 29th that I wouldn’t be surprised if the Fed didn’t cut. (Watch)

And just in case things aren’t spicy enough?

U.S. President Donald Trump put another shot across Chairman Powell’s bow saying he’d “love to fire his ___” and urging Treasury Secretary Scott Bessent to “work on” Powell to lower rates.

Reminds me of the Sopranos.

MyPOV: The Fed still has no idea whether it’s fighting inflation, saving jobs, or just trying to stay relevant. One minute they’re doves, the next they’re hawks, and half the time they sound like a flock of pigeons arguing over breadcrumbs.

Powell says they’re “driving in the fog” but I don’t think it’s dawned on Team Powell that perhaps they’re the ones who created the fog in the first place.

Keith’s Investing Tip: Buy the very best companies you can – meaning those making “must have” products and services, with fortress-like balance sheets, defensible margins and excellent leadership capable of succeeding practically no matter what the Fed does next.

Names like those the One Bar Ahead® Family knows well.

5 – Denmark, now brought to you by Novo Nordisk

Here’s something you don’t see every day.

Denmark just posted its fastest economic growth in years, and it’s almost entirely thanks to one company — Novo Nordisk. (Read)

GDP jumped 2.3% in Q3, the biggest quarterly gain since 2021. Take out pharma, and the economy would have grown just 0.7% … or 70% less!

I can only recall a handful of times in my career that I’ve seen one company’s sales curve take over the national GDP chart.

Should you buy Novo Nordisk?

I could absolutely make the argument.

Novo is down 49% this year, yet it’s single-handedly powering Denmark’s fastest GDP growth in years. GLP-1s are becoming infrastructure inside health systems around the world.

It could be one heckuva buy, but I can think of a few other names I’d rather own.

My personal favourites remain those with far more dominant positions.

Here’s why I say that.

As good as it is, GLP-1 is an “at risk” technology and Novo Nordisk is but one innovation (from somebody else) away from losing everything.

What investors are missing is simple.

Novo isn’t just competing against Eli Lilly or another drug company like most investors think or the media would have you believe.

No, the company is competing against every lab, every AI drug platform, every metabolic moonshot chasing the next breakthrough that leapfrogs injectables entirely.

Oral GLP-1s. Gene edits. Next-gen metabolic modulators. Even AI-designed compounds targeting obesity from completely different biological angles.

And that’s not even counting real exercise or diet management which, contrary to what the easy button crowd wants to believe, actually goes a long way. Serious and real health concerns are different so that’s not a dig, btw.

The point I want to make is that if any one of those hits, Novo’s dominance can go from fortress to freefall in a hurry.

Keith’s Investing Tip: Great companies can still be terrible trades when innovation risk is rising. That’s why I prefer owning the players building platforms — not products — because platforms capture the upside practically no matter who makes the next breakthrough.